The invention relates to compounds of formula (I) and salts thereof:

##STR00001##

wherein ring A and R.sup.1-R.sup.2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

A condensed cyclic compound represented by Formula 1: ##STR00001## wherein in Formula 1, A.sub.1, A.sub.11, X.sub.21, XY.sub.1, XY.sub.11, R.sub.4, R.sub.14, b4, b14, c1, and c11 are as described in the specification.

A condensed cyclic compound represented by Formula 1: ##STR00001## wherein in Formula 1, A.sub.1, A.sub.11, X.sub.21, XY.sub.1, XY.sub.11, R.sub.4, R.sub.14, b4, b14, c1, and c11 are as described in the specification.

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K.sub.d of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K.sub.d of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.

A novel crystalline form of rifaximin and process for its preparation are described. A pharmaceutical composition comprising crystalline rifaximin is also described.

The invention relates to an electronic device containing at least one compound of formula (I) or (II) in an organic layer. The invention further relates to a method for producing the electronic device and the use of a compound of formula (I) or (II) in an electronic device.

The invention relates to an electronic device containing at least one compound of formula (I) or (II) in an organic layer. The invention further relates to a method for producing the electronic device and the use of a compound of formula (I) or (II) in an electronic device.

The invention relates to metal complexes and to electronic devices, in particular organic electroluminescence devices, containing said metal complexes.

The invention relates to metal complexes and to electronic devices, in particular organic electroluminescence devices, containing said metal complexes.